SCHEMBL20993121

SCHEMBL20993121

CCCCNc1nc(N)nc(C)c1Cc1cc(P(=O)(OCC)OCC)ccc1OC

nearest known ligand 0.80

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 20/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31410728 1.00 TLR7 (0.80) TLR7
SCHEMBL30037368 1.00 TLR7 (0.80) TLR7
SCHEMBL20212172 0.89 TLR7 (1.00) TLR7
SCHEMBL30037544 0.86 TLR7 (0.81) TLR7
SCHEMBL21475792 0.86 TLR7 (0.81) TLR7
SCHEMBL31410733 0.86 TLR7 (0.81) TLR7
SCHEMBL20223043 0.83 TLR7 (0.85) TLR7
SCHEMBL30037437 0.82 TLR7 (1.00) TLR7
SCHEMBL20212200 0.82 TLR7 (1.00) TLR7
SCHEMBL20212180 0.82 TLR7 (0.71) TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110177780-B Pyrimidine compounds containing acidic groups 阿普罗斯治疗公司 2022-11-01 — — CN disclosed
US-11173157-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators Apros Therapeutics, Inc. (US) 2021-11-16 — — US disclosed
US-20210000826-A1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS Apros Therapeutics, Inc. 2021-01-07 — — US disclosed
US-10786502-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators Apros Therapeutics, Inc. (US) 2020-09-29 — — US disclosed
US-20190314372-A1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS Apros Therapeutics, Inc. 2019-10-17 — — US disclosed
US-10287253-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators Apros Therapeutics, Inc. (US) 2019-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210000826-A1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS TLR7, TLR9, STING1 TLR7 1/4885
US-20190314372-A1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS MAVS, TLR7, STING1 TLR7 2/4885
US-10287253-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators TLR7, TLR9, MAVS TLR7 1/4885
US-11173157-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators TLR7, TLR9, MAVS TLR7 1/4885
US-10786502-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators TLR7, TLR9, MAVS TLR7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback